Cardinal Health, Inc. (CAH) Q3 2026 Earnings Call Transcript – Image for illustrative purposes only (Image credits: Unsplash)
Dublin, Ohio – Cardinal Health reported third-quarter fiscal 2026 results that showcased resilience across its core operations, even as external pressures like tariffs weighed on certain segments. The pharmaceutical distributor posted revenue growth amid strong demand for specialty products and generics, leading executives to lift their annual earnings guidance. This performance underscores the company’s strategic push into higher-margin areas as it navigates a complex supply chain landscape.[1][2]
Key Financial Metrics Exceed Expectations
The company recorded revenue of $60.9 billion for the quarter ended March 31, 2026, marking an 11 percent increase from the prior year. This figure slightly missed some analyst projections but reflected solid volume growth in pharmaceuticals.[1][3]
Non-GAAP operating earnings rose 18 percent to $956 million, while non-GAAP diluted earnings per share climbed 35 percent to $3.17, surpassing estimates around $2.80. GAAP figures told a different story, with operating earnings down 30 percent to $509 million and diluted EPS falling 20 percent to $1.69, primarily due to a $184 million goodwill impairment charge in the Navista and ION reporting unit.[1]
Gross profit expanded 18 percent to $2.5 billion, supported by acquisitions and operational efficiencies. Adjusted free cash flow reached $1.7 billion in the quarter, bolstering the balance sheet with nearly $4 billion in cash on hand.[2]
Segment Performance Highlights Strengths and Challenges
The Pharmaceutical and Specialty Solutions segment, Cardinal Health’s largest unit, drove much of the quarter’s success. Revenue grew 11 percent to $56.1 billion, fueled by sales of brand and specialty pharmaceuticals to existing customers. Segment profit increased 18 percent to $784 million, aided by positive generics performance and maintained economics on distribution contracts despite Inflation Reduction Act pricing adjustments.[1][2]
GLP-1 medications contributed six percentage points to growth, though overall growth moderated from prior quarters. Oncology sales surged over 30 percent, and the company expects specialty revenue to exceed $50 billion for the full year.[2]
In contrast, the Global Medical Products and Distribution segment faced headwinds. Revenue held flat at $3.1 billion, with lower distribution volumes offset by over five percent growth in Cardinal Health-branded products. Profit declined 36 percent to $25 million, hit by the net impact of tariffs, including about $200 million in IEEPA-related costs.[3]
| Segment | Q3 FY26 Revenue | YoY Change | Segment Profit | YoY Change |
|---|---|---|---|---|
| Pharmaceutical & Specialty Solutions | $56.1B | +11% | $784M | +18% |
| Global Medical Products & Distribution | $3.1B | 0% | $25M | -36% |
| Other | $1.7B | +31% | $179M | +34% |
The “Other” category, encompassing at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics, posted the strongest gains. Revenue jumped 31 percent to $1.7 billion, with profit up 34 percent to $179 million, driven by robust demand and the Advanced Diabetes Supply acquisition.[1]
Guidance Raised on Operational Momentum
Executives expressed confidence in the business trajectory, raising fiscal 2026 non-GAAP EPS guidance to $10.70 to $10.80, implying 30 to 31 percent growth from the prior year. This adjustment, a $0.50 increase at the midpoint, stems from stronger segment profits and below-the-line benefits like a lower effective tax rate of about 19 percent.[1][2]
Adjusted free cash flow outlook narrowed to $3.3 billion to $3.7 billion. Segment projections improved: Pharmaceutical profit growth now at 22 to 23 percent, and Other at 36 to 38 percent. Pharma revenue is expected at the lower end of 15 to 17 percent due to product mix shifts.[3]
- Pharmaceutical & Specialty: Revenue +15-17%; Profit +22-23%
- Global Medical: Revenue +1-3%; Profit ~$150M
- Other: Revenue +26-28%; Profit +36-38%
“An excellent third quarter extends our FY26 momentum, due to the durability and resilience of our business,” said CEO Jason Hollar.[1]
Strategic Initiatives Bolster Long-Term Position
Cardinal Health advanced key priorities, including debt reduction with a $100 million early term loan repayment, lowering the leverage ratio to 3.0 times within its target range. Year-to-date share repurchases totaled $1 billion, exceeding baseline plans by $250 million.[1]
Acquisitions like Solaris Health, a urology management services organization, and tuck-ins in The Specialty Alliance enhance the community care model. Expansions in nuclear theranostics, including Actinium-225 production, position the firm for growth in advanced therapies. Executives noted progress in the GMPD improvement plan, focusing on simplification and supply chain resiliency.[2]
Stakeholders, from hospital customers to shareholders, benefit from these moves. Hospitals gain access to specialized distribution and data analytics, while investors see rising cash flows supporting returns. Tariff uncertainties persist, with potential refunds under review, but the company maintains no impact in current guidance.[2]
Looking ahead, Cardinal Health remains optimistic about fiscal 2027, citing sustained demand trends in specialty medicine and demographics favoring at-home care. The raised outlook signals to markets that operational execution can offset macroeconomic risks, setting the stage for continued value creation in a vital healthcare supply chain.